DEPENDENCE OF GRAVITY OF LIVER DISEASE FROM REPLICATIVE ACTIVITY OF VIRUS HEPATITIS B AND D

Abstract

The article is devoted to the study of the connection between the replicative activity of HBV DNA and HDV RNA with the formation of CP at all stages of development of chronic hepatitis of viral nature, evidence that a high level of HBV DNA is a pronounced predictor of liver cirrhosis (LC) progression. The purpose of the study is to study the dependence of the severity of liver damage on the replicative activity of the hepatitis B virus and D. Materials and methods. The study included 67 patients with cirrhosis of the liver in the outcome of viral hepatitis B and 140 patients with an outcome of cirrhosis against the background of chronic hepatitis B + D. The clinical stage of LC was determined according to the Child-Puy classification. Results. A direct link has been established between the increase in the viral load of HBV DNA and HDV RNA with the duration of the disease. A tendency was revealed to increase the severity of the disease in patients with LC of viral etiology with an increase in viral load. The biochemical indices of blood showed a tendency to an increase in the level of cytolytic enzymes against the background of high replicative activity of HBV DNA and HDV RNA. The conclusion. Thus, a high level of HBV DNA is a pronounced predictor of the progression of LC at all stages of the pathological process.

Keywords

liver cirrhosis / HBV infection / HDV infection / viral load

References

[1] Ивашкин В.Т., Лапина Т.Л. Гастроэнтерология: национальное руководство. ГЭОТАР - Медиа. 2008.

[2] Ивашкин В.Т. Болезни органов пищеварения (для специалистов и врачей общей практики). Библиотека Российского медицинского журнала. 2007; 2(9): 62-7.

[3] Shi W., Zhang Z., Ling C., Zheng W. et al. Hepatitis B virus sub genotyping: history, effects of recombination, misclassifications, and corrections. Infection Genetics and Evolution, 2013; 16: 355-61.

[4] Вялов С.С. Клинико-патофизиологические аспекты гепатопротективной терапии у лиц молодого возраста. Доктор ру. 2011; 5 (64): 42-8.

[5] Cavalli M., Pan G., Nord H. et al. Genetic prevention of HCV induced liver fibrosis by allele-specific down-regulation of MERTK. Hepatology Resurge. 2016: 10.1111/ hepr.12810.

[6] Gane E. Does Antiviral therapy Alter the outcome in HBV and HCV cirrhosis? Hepatology International. Bangkok, 2011; 1(5): 9.

[7] Iloeje U.H., Yang H.I., Su J., Jen C.L. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 2006; 3 (130): 678-86.

[8] Rehman S.U., Rauf M., Abbas Z., Hamed M.H. et al. Role of Some Predominant Host Immunomodulators’ Single Nucleotide Polymorphisms in Severity of Hepatitis B Virus and Hepatitis C Virus Infection. Viral Immunology, 2016.

[9] Вялов С.С. Скрининговые методы выявления фиброза печени. Архив внутренней медицины. Москва, 2012; 3 (5): 48-57.

[10] Вялов С.С. Использование скрининговых методов для выявления стеатогепатоза. Тезисы XVII конгресс «Гепатология сегодня». М., 2012.

[11] Павлов Ч.С., Глушенков Д.В., Ондос Ш.А., Ивашкин В.Т. «Фибро-Макс» - комплекс неинвазивных тестов для диагностики хронических диффузных заболеваний печени. Гепатологический форум. 2008; 3: 22-7.

[12] Piratvisuth T. Enlightening the Future: Coming Era of individualized Treatment of Chronic hepatitis B. Hepatology International.-Bangkok, 2011; (1) 5: 10.

RIGHTS & PERMISSIONS

Eco-vector